How to Buy Cullinan Therapeutics Stock
Cullinan Therapeutics Inc
Cullinan Oncology Inc. , a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States.
Cullinan Therapeutics stock last closed at $7.64, down 6.72% from the previous day, and has decreased 58.16% in one year. It has overperformed other stocks in the Biotechnology industry by 0.01 percentage points. Cullinan Therapeutics stock is currently +11.53% from its 52-week low of $6.85, and -61.59% from its 52-week high of $19.89.
As of Aug 25, 2025, there are 59.01M CGEM shares outstanding. The market capitalization of CGEM is $450.87M. In the last 24 hours, 221,000 CGEM shares were traded.
How to Buy Cullinan Therapeutics Stock
Wondering how to invest in Cullinan Therapeutics stock? Here's how.
- Decide where to buy Cullinan Therapeutics stock: You need to decide on an online brokerage, but don't worry - we've tested dozens of online brokerages and apps to help you figure out where to buy Cullinan Therapeutics stock.
- Create a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Put funds into your investment account: Choose your payment method and add your info.
- Research Cullinan Therapeutics stock: The Cullinan Therapeutics ticker symbol is CGEM. Is Cullinan Therapeutics stock a good investment? Should you buy shares of CGEM? How do CGEM's underlying business fundamentals look? Do top analysts think Cullinan Therapeutics is a good buy? Why has CGEM's stock price moved recently? (Hint: Our stock market research tools can help you decide if CGEM is a good stock to buy).
- Execute your CGEM trade: Decide if you will purchase CGEM shares at the current market price or use a limit order to buy CGEM stock at a given price.
- Watch your investment in CGEM: Create a watchlist to key updates about your new investment in Cullinan Therapeutics stock.
Step 1: Decide where to buy Cullinan Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy CGEM stock.
Our favorite brokerage: eToro
Based on our research, eToro is the best online stock brokerage. Here's why:
- Invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to world markets: From Technology to Real Estate, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've selected the best brokerage, you need to fill out some personal info so you can buy CGEM today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to open a new trading account.
- Send your data by clicking the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you've created your account on apps for stocks, your next step is to transfer the money for your investment:
Check out the tutorial below to see the process of transferring money into your new brokerage account.
Step 4: Research Cullinan Therapeutics stock
After you have selected the best place to buy Cullinan Therapeutics stock, it's very important to analyze their stock prior to investing, so you truly understand the risk and opportunity.
Cullinan Therapeutics shares quick numbers
Cullinan Therapeutics Overview
WallStreetZen was built to help average investors perform better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on CGEM's stock page.
Is CGEM stock undervalued or overvalued?
You can use many financial metrics, analyses, models, and charts to gauge CGEM's intrinsic value.
Using relative valuations measures:
- CGEM may be undervalued based on its P/B ratio of 0.82x, relative to Biotechnology industry P/B ratio of 4.53x
You can access more valuation research on CGEM's stock here.
CGEM Financial Health Summary
Pros:
- There are more short-term assets than long-term liabilities on the CGEM balance sheet.
- There are more short-term assets than short-term liabilities on the CGEM balance sheet.
- CGEM has cash burn of 150211000. It has enough cash and short-term investments to cover this for at least one year.
- CGEM has a low debt to equity ratio of 0.05.
Cons:
- CGEM has $303.83M in cash and short term investments. This is not sufficient to cover its annual cash burn of $150.21M.
Is it a good time to buy Cullinan Therapeutics stock, according to Wall Street analysts?
Out of 6 sell side analysts who track CGEM, the consensus analyst rating on CGEM is a Strong Buy
It's important to note that analyst forecasts are not recommendations, nor are they financial advice.
Latest CGEM Analyst Upgrades/Downgrades
Bradley Canino, a bottom 12% analyst from Stifel Nicolaus maintains CGEM with a strong buy rating and lowers their CGEM price target from $23.00 to $19.00, on Feb 28, 2025.
You can dig deeper into what analysts are forecasting on the Cullinan Therapeutics stock forecast page.
CGEM Technical Indicators
CGEM Performance Numbers
Last year, CGEM revenue was $0.00. Over the last 4 year, CGEM's revenue has increased by -100% per year. This was slower than the Biotechnology industry average of 65.04%.
You can research CGEM's earnings and revenue performance here.
Who is buying/selling CGEM?
Over the past 12 months, insiders at CGEM have sold more shares than they have bought.
Nadim Ahmed, President and CEO of CGEM, was the latest CGEM insider to sell. They sold $106,872.37 worth of CGEM stock on Feb 25, 2025.
Research more about who owns CGEM shares here.
Can I get consistent income from CGEM stock?
No, Cullinan Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about CGEM
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other traders have to say.
Step 5: Execute your CGEM trade
You have two main options:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are generally the easiest way to buy. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to ensure you're buying or selling at a specific price, place a limit order.
Press the Open button and eToro will place your order.
If you require more help with buying stocks on eToro, watch the helpful video below:
Step 6: Watch your investment in CGEM
Now that you own some shares in CGEM, you'll want to keep up with your investment.
Add CGEM to a watchlist to track the most important metrics related to your CGEM stock.
CGEM Feed
How to Buy Stock in Cullinan Therapeutics
To reiterate, here are the 6 steps to buy stock in Cullinan Therapeutics:
- Decide where to buy Cullinan Therapeutics stock
- Create a brokerage account
- Put funds into your investment account
- Research Cullinan Therapeutics stock
- Execute your CGEM trade
- Watch your investment in CGEM
If you need a brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to get the latest news on your new investment in Cullinan Therapeutics, create a watchlist on WallStreetZen today.
More Content You Might Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.